Frontotemporal Dementia Pipeline Insight
DelveInsight’s,“Frontotemporal Dementia (FTD) – Pipeline Insights, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Frontotemporal Dementia Understanding
Frontotemporal Dementia (FTD): Overview
Frontotemporal dementia (FTD) or frontotemporal degenerations refers to a group of disorders caused by progressive nerve cell loss in the brain's frontal lobes (the areas behind your forehead) or its temporal lobes (the regions behind your ears). The nerve cell damage caused by frontotemporal dementia leads to loss of function in these brain regions, which variably cause deterioration in behavior, personality and/or difficulty with producing or comprehending language.
Based on the distinct patterns of signs and symptoms, three different clinical syndromes have been grouped together under the category of “frontotemporal dementia” (FTD):
- Behavioral variant frontotemporal dementia (bvFTD)
- Semantic variant primary progressive aphasia (svPPA)
- Non-fluent/agrammatic variant primary progressive aphasia (nfvPPA)
Common behavioral symptoms of frontotemporal dementia include:
- inappropriate actions
- apathy, or lack of interest or enthusiasm in activities
- lack of inhibition or restraint
- neglect of personal hygiene and care
- compulsive behavior
Common language-related symptoms of frontotemporal dementia include:
- difficulty speaking or understanding speech
- language recall problems
- loss of reading and writing skills
- difficulty with social interactions
Some of the tests used to diagnose frontotemporal dementia include:
- Blood tests: These can help identify other possible causes.
- Neuropsychological testing: These tests check judgment and memory skills, and help determine what type of dementia a person may have.
- Brain imaging: Doctors will check for tumors or blood clots.
- MRI: A magnetic resonance imaging (MRI) test gives doctors a detailed image of brain.
- CT scan: A computerized tomography (CT) scan creates images of brain in layers.
There are no specific treatments for any of the frontotemporal subtypes. There are medications that can reduce agitation, irritability and/or depression. These treatments should be used to help improve quality of life. Common treatments include:
- Some antidepressants can help reduce the behavioral problems caused by changes to the brain
It can help learn to cope with speech difficulties. A speech therapist can also help find alternative ways to communicate.
Frontotemporal Dementia Emerging Drugs Chapters
This segment of the Frontotemporal Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Frontotemporal Dementia Emerging Drugs
- PR006: Prevail Therapeutics
PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). Like PR001, PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9.
AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with Abbvie. In June 2018, this antibody received orphan drug designation from the U.S. FDA for the treatment of frontotemporal dementia. Sortilin is a type I membrane glycoprotein in the vacuolar protein sorting 10 protein (Vps10p) family. Sortilin is abundantly expressed in the central nervous system. Targeting the sortilin-progranulin axis was reported to improve outcomes associated with progranulin insufficiency in preclincial models.
Further product details are provided in the report……..
Frontotemporal Dementia: Therapeutic Assessment
This segment of the report provides insights about the different Frontotemporal Dementia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Frontotemporal Dementia
There are approx. 5+ key companies which are developing the therapies for Frontotemporal Dementia. The companies which have their Frontotemporal Dementia drug candidates in advanced stage, i.e. phase III include, Alector, etc.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of
Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant proteins
- Monoclonal antibodies
- Gene therapies
- Progranulin protein replacements
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Frontotemporal Dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal Dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal Dementia drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal Dementia.
- The IND for PR006 for the treatment of FTD-GRN is active, and the FDA has granted Orphan Drug Designation for PR006 for the treatment of FTD and Fast Track Designation for FTD-GRN.
- In July 2020, Alector started a Phase 3, placebo-controlled trial for AL001. Called INFRONT-3, it will enroll 180 people between 18 and 85 who are at risk of or have frontotemporal dementia due to heterozygous mutations in the progranulin gene. It is taking place at 47 sites in North America, Australia, and Europe, and will run through 2023.
Frontotemporal Dementia Report Insights
- Frontotemporal Dementia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Frontotemporal Dementia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Frontotemporal Dementia drugs?
- How many Frontotemporal Dementia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal Dementia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal Dementia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Frontotemporal Dementia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Prevail Therapeutics
- Alector Inc.